Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Kahl Shares Antibody-Drug Conjugate Updates in Lymphoma

July 18th 2018

With promising data of brentuximab vedotin and inotuzumab ozogamicin leading the way, antibody-drug conjugates are beginning to make a greater impact on the lymphoma treatment landscape.

Selinexor FDA Submission Started for Multiple Myeloma

July 18th 2018

A rolling submission of an FDA new drug application (NDA) has been submitted for selinexor for the treatment of patients with penta-refractory multiple myeloma.

Expert Highlights Potential of Moxetumomab Pasudotox in Hairy Cell Leukemia

July 18th 2018

Robert J. Kreitman, MD, discusses the potential of moxetumomab pasudotox as a treatment for patients with hairy cell leukemia.

Dr. Kambhampati on the Impact of Next-Generation Sequencing in AML

July 18th 2018

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the impact of next-generation sequencing (NGS) in acute myeloid leukemia (AML).

Dr. Flinn on the RELEVANCE Trial in Follicular Lymphoma

July 17th 2018

Ian Flinn, MD, PhD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the RELEVANCE trial in follicular lymphoma.

Dr. Pinilla-Ibarz Discusses Advancements in CML

July 16th 2018

Javier A. Pinilla-Ibarz, MD, PhD senior member, Moffit Cancer Center, discusses the recent advances in chronic myeloid leukemia (CML). Pinilla-Ibarz says that he and colleagues do not expect much in the field after other recent advancements, but he is still surprised to see what is being concentrated on today.

Dr. Madduri on SWOG S0777 in Multiple Myeloma

July 16th 2018

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses evidence supporting the use of a triplet regimen versus a doublet regimen in elderly and transplant ineligible patients with multiple myeloma.

Pembrolizumab Data Reviewed in Classical Hodgkin Lymphoma

July 15th 2018

George F. Geils, Jr, MD, discussed the clinical efficacy and adverse event management techniques for pembrolizumab as a treatment for patients with classical Hodgkin lymphoma.

CAR T-cell Therapies Offer Hope for DLBCL

July 15th 2018

Chimeric antigen receptor T-cell therapies have quickly moved from early phase clinical trials to FDA approval for diffuse large B-cell lymphoma, with research now exploring ways to shift these agents earlier in the treatment paradigm.

Expert Discusses the Discontinuation of TKIs in Treatment Landscape of CML

July 14th 2018

Gabriela S. Hobbs, MD, discusses how discontinuing tyrosine kinase inhibitors will change the treatment landscape and other strategies for treating patients with chronic myeloid leukemia.

Dr. Barrientos on the Challenges in CLL

July 14th 2018

Jacqueline D. Barrientos, MD, MS, CLL Research and Treatment Program, Northwell Health Systems, discusses the current challenges oncologists are faced with in the field of chronic lymphocytic leukemia.

Dr. Lesokhin Discusses Exciting Advances in Multiple Myeloma

July 14th 2018

Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses some of the exciting advancements currently happening in the field of multiple myeloma.

Dr. Talley on Clinical Trials for Patients With Chronic Leukemias

July 13th 2018

Robert L. Talley, MD, hematologist/medical oncologist, Centerpoint Medical Center, Sarah Cannon Cancer Institute, discusses clinical trials for patients with chronic leukemias.

Dr. Kambhampati on BCL-2 Inhibition in Acute Myeloid Leukemia

July 13th 2018

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses BCL-2 inhibition in acute myeloid leukemia (AML).

FDA Approval Sought for Frontline Venetoclax Combo in AML

July 12th 2018

A supplemental New Drug Application has been submitted to the FDA for venetoclax (Venclexta) for use in combination with a hypomethylating agent or low-dose cytarabine for the first-line treatment of patients with acute myeloid leukemia.

Frontline Ibrutinib Plus R-CHOP Misses Primary Endpoint in Phase III DLBCL Trial

July 11th 2018

Combining ibrutinib with standard R-CHOP did not improve event-free survival versus R-CHOP alone in the first-line setting for patients with diffuse large B-cell lymphoma.

Dr. Flinn on CAR T-Cell Therapy in Non-Hodgkin Lymphoma

July 11th 2018

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses chimeric antigen receptor (CAR) T-cell therapy in non-Hodgkin lymphoma (NHL).

Dr. Abramson Discusses Lisocabtagene Maraleucel in NHL

July 10th 2018

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses lisocabtagene maraleucel (JCAR017; liso-cel) as a treatment for patients with non-Hodgkin lymphoma.

Dr. Knudsen Discusses the Rationale of the DALIAH Trial in MPNs

July 10th 2018

Trine Alma Knudsen, MD, PhD student, Department of Haematology, Zealand University Hospital, Roskilde, Denmark, discusses the rationale of the DALIAH trial in patients with myeloproliferative neoplasms.

Dr. Talley on the CAPTIVATE Trial in CLL

July 10th 2018

Robert L. Talley, MD, hematologist/medical oncologist, Centerpoint Medical Center, Sarah Cannon Cancer Institute, discusses the CAPTIVATE trial in patients with chronic lymphocytic leukemia (CLL).